123 related articles for article (PubMed ID: 33031796)
1. Sulfoxythiocarbamate S-4 inhibits HSP90 in human cutaneous squamous cell carcinoma cells.
Zhang Y; VanHecke GC; Ahn YH; Proby CM; Dinkova-Kostova AT
Eur J Pharmacol; 2020 Dec; 889():173609. PubMed ID: 33031796
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
[TBL] [Abstract][Full Text] [Related]
3. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
[TBL] [Abstract][Full Text] [Related]
4. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
5. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
Jung J; Kwon J; Hong S; Moon AN; Jeong J; Kwon S; Kim JA; Lee M; Lee H; Lee JH; Lee J
Bioorg Med Chem Lett; 2020 Jun; 30(12):127165. PubMed ID: 32305165
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
[TBL] [Abstract][Full Text] [Related]
8. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
9. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
Wang Y; Koay YC; McAlpine SR
Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
[TBL] [Abstract][Full Text] [Related]
10. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
11. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
Walsby E; Pearce L; Burnett AK; Fegan C; Pepper C
Oncotarget; 2012 May; 3(5):525-34. PubMed ID: 22619113
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
[TBL] [Abstract][Full Text] [Related]
13. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.
Djuzenova CS; Blassl C; Roloff K; Kuger S; Katzer A; Niewidok N; Günther N; Polat B; Sukhorukov VL; Flentje M
Cancer Biol Ther; 2012 Apr; 13(6):425-34. PubMed ID: 22286776
[TBL] [Abstract][Full Text] [Related]
14. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
Wainberg ZA; Anghel A; Rogers AM; Desai AJ; Kalous O; Conklin D; Ayala R; O'Brien NA; Quadt C; Akimov M; Slamon DJ; Finn RS
Mol Cancer Ther; 2013 Apr; 12(4):509-19. PubMed ID: 23395886
[TBL] [Abstract][Full Text] [Related]
16. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi M; Liu F; Tavorath R; Rosen N
Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672
[TBL] [Abstract][Full Text] [Related]
18. Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
Cheng W; Ainiwaer A; Xiao L; Cao Q; Wu G; Yang Y; Mao R; Bao Y
Mol Med Rep; 2015 Aug; 12(2):2451-6. PubMed ID: 25955495
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
[TBL] [Abstract][Full Text] [Related]
20. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
